IP Library Granted Patent US 8,017,777
Granted Patent B2
US 8,017,777 · App. 12/316,861 · Granted Sep 13, 2011

Process for the preparation of buprenorphine and derivatives for buprenorphine

Assignee: Mallinckrodt LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,777
App. No.
12/316,861
Granted
Sep 13, 2011
Kind
B2
Abstract

The invention generally provides processes for the production of buprenophine and derivatives of buprenorphine. In particular, the process may encompass synthetic routes for the production of buprenorphine or derivatives of buprenorphine from norhydromorphone or derivatives of norhydromorphone.

Claims (42)

1. A process for the preparation of compound 8 according to the following reaction scheme:

wherein:

R 0 and R 8 are independently selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

R 1 , R 7 and R 8a are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, halogen, OR b , hydrocarbyl, and substituted hydrocarbyl, or R 2 and R 3 may together form {−}=O;

R a is a hydroxyl protecting group;

R b is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

M is selected from Group IA metal salts, and Group IIA metal salts;

X, and X 2 are independently selected from the group consisting of bromide, and chloride;

X 1 is bromide or chloride when R 4 is hydrogen, and X 1 is R 4 when R 4 is not hydrogen; and

Y is selected from the group consisting of oxygen, sulfur, and nitrogen.

2. The process of claim 1 , wherein:

R 1 , R 7 and R 8a are independently selected from the group consisting of hydrogen alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, and substituted aryl;

M is selected from the group consisting of NaR, LiR, or RMgX 3 , where X 3 is chloride or bromide and R is a hydrocarbyl or substituted hydrocarbyl;

X, X 1 , and X 2 are each bromide; and

Y is oxygen.

3. The process of claim 1 , wherein

R 1 is {−}CH 2 -cyclopropyl;

R 2 , R 3 , R 5 , and R 6 are each hydrogen;

R 7 is methyl;

R 8 is tertiary butyl; and

Y is oxygen.

4. The process of claim 1 , wherein the molar ratio of compound 1 to oxygen protecting group is from about 1:1 to about 1:3, the reaction is conducted in the presence of a solvent selected from the group consisting of an organic solvent, a protic solvent, an aprotic solvent, and combinations thereof, and the reaction is conducted at a temperature ranging from about 20° C. to about 50° C.

5. The process of claim 4 , wherein the oxygen protecting group is selected from the group consisting of aryl-CH 2 Br.

6. The process of claim 1 , wherein the molar ratio of compound 2 to hydrocarbyl orthoformate to proton donor is from about 1:1:1.5 to about 1:2:3, the reaction is conducted in the presence of an aprotic solvent, and the reaction is conducted at a temperature ranging from about 20° C. to about 120° C.

7. The process of claim 6 , wherein the hydrocarbyl orthofomate is selected from the group consisting of trimethyl orthoformate, and triethyl orthoformate, and the proton donor is selected from the group consisting of MeSO 3 H, poly H 3 PO 4 , H 3 PO 4 , H 2 SO 4 , HCl, HBr, HClO 4 , HI, HNO 3 , CF 3 SO 3 H, p-methyltoluenesulfonic acid, HClO 3 , HBrO 4 , HIO 3 , and HIO 4 .

8. The process of claim 6 , wherein the reaction is conducted in the presence of an alcohol-containing solvent.

9. The process of claim 8 , wherein X is bromine added in an amount ranging from about 2 to about 2.5 equivalents for each equivalent of compound 2.

10. The process of claim 1 , wherein the molar ratio of compound 3 to proton acceptor is from about 1:1 to about 1:10, the reaction is conducted in the presence of an aprotic solvent, and the reaction is conducted at a temperature ranging from about 40° C. to about 120° C.

11. The process of claim 10 , wherein the proton acceptor is selected from the group consisting of hydroxide salts.

12. The process of claim 1 , wherein the molar ratio of compound 4 to alcohol scavenger is from about 1:0.3 to about 1:3, the reaction is conducted in the presence of an aprotic solvent, and the reaction is conducted at a temperature ranging from about 0° C. to about 80° C.

13. The process of claim 12 , wherein the alcohol scavenger is a methanol scavenger selected from the group consisting of P 2 O 5 , POCl 3 , POBr 3 , PCl 3 , PBr 3 , SOCl 2 , SOBr 2 , MeSO 2 Cl, (MeSO 2 ) 2 O, SO 3 , (CF 3 SO 2 ) 2 O, (CF 3 CO) 2 O, and (CR 3 CO) 2 O, wherein R is an alkyl group.

14. The process of claim 1 , wherein the molar ratio of compound 5 to

is from about 1:1 to about 1:10, the reaction is conducted in the presence of an organic solvent, and the reaction is conducted at a temperature ranging from about 20° C. to about 120°.

15. The process of claim 14 , wherein R 7 is a methyl group.

16. The process of claim 1 , wherein the reduction is catalytic reduction, the molar ratio of compound 6 to catalyst is from about 1:0.0005 to about 1:0.05, the reaction is conducted in the presence of an organic solvent, the reaction is conducted under pressurized hydrogen, and the reaction is conducted at a temperature ranging from about 20° C. to about 120° C.

17. The process of claim 16 , wherein the catalyst is a transition metal catalyst selected from the group consisting of Pd/C, Pt/C, Ru/C, and Rh/C; and the hydrogen pressure is between about 0 and about 500 PSI.

18. The process of claim 1 , wherein the molar ratio of compound 7 to R 8 M is from about 1:2 to about 1:10, the reaction is conducted in the presence of an aprotic solvent, and the reaction is conducted at a temperature ranging from about 60° C. to about 120° C.

19. The process of claim 18 , wherein R 8 is tertiary butyl.

20. The process of claim 19 , wherein M is MgCl.

21. The process of claim 1 , wherein the yield of compound 8 is from about 8% to about 20%; and the purity of compound 8 is at least 98% as determined by chromatography.

22. The process of claim 1 , wherein the configuration of carbons 5, 13, 14, and 9, respectively, of any of compounds 1 to 8 is selected from the group consisting RRRS, RRSS, SRRS, SRSS, RSRR, RSSR, SSRR, and SSSR, provided that the C15 and the C16 atoms are both either on the alpha face of the molecule or the beta face of the molecule.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2009
From: WANG, PETER W.; JIANG, TAO; CANTRELL, GARY L.; BERBERICH, DAVID W.; TRAWICK, BOBBY N.; LIAO, SUBO
To: MALLINCKRODT INC.
Reel/Frame 022182/0240 →
Continuity (2)
Provisional Application 61014090 · Dec 17, 2007
Related Publication 20090156817A1 · Jun 18, 2009